Inupadenant (EOS-850) drochloride is an orally active, highly selective A2A receptor antagonist. Inupadenant drochloride is not brain-penetrant. Inupadenant drochloride has potent anti-tumor activity.
References:
[1]. Laurence Buisseret, et al. Phase 1 trial of the adenosine A2Areceptor antagonist inupadenant (EOS-850): Update on tolerability, and antitumor activity potentially associated with the expression of the A2A receptor within the tumor. Journal of Clinical Oncology. Volume 39, Issue 15_suppl.
















